ALT Altimmune Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ALT

Price (delayed)

$15.98

Market cap

$613.58M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.03

Enterprise value

$463.61M

Highlights
ALT's quick ratio is up by 28% QoQ
The equity has increased by 9% since the previous quarter
ALT's revenue is up by 35% year-on-year but it is down by 17% since the previous quarter
The gross profit has grown by 35% YoY but it has contracted by 17% from the previous quarter
Altimmune's net income has shrunk by 169% YoY and by 22% QoQ
Altimmune's EPS has decreased by 34% YoY and by 6% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: https://altimmune.com/
Peers: ONTX OPK

Key stats

What are the main financial stats of ALT
Market
Shares outstanding
38.4M
Market cap
$613.58M
Enterprise value
$463.61M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.41
Price to sales (P/S)
91.32
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
68.08
Earnings
Revenue
$6.81M
EBIT
-$62.17M
EBITDA
-$61.88M
Free cash flow
-$54.05M
Per share
EPS
-$2.03
Free cash flow per share
-$1.39
Book value per share
$6.63
Revenue per share
$0.17
TBVPS
$6.46
Balance sheet
Total assets
$264.25M
Total liabilities
$17.81M
Debt
$0
Equity
$246.44M
Working capital
$235.37M
Liquidity
Debt to equity
0
Current ratio
24.96
Quick ratio
23.55
Net debt/EBITDA
2.42
Margins
EBITDA margin
-908.6%
Gross margin
100%
Net margin
-881.4%
Operating margin
-915.6%
Efficiency
Return on assets
-28.4%
Return on equity
-31.9%
Return on invested capital
-86.7%
Return on capital employed
-24.4%
Return on sales
-913%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALT stock price

How has the Altimmune stock price performed over time
Intraday
0.76%
1 week
11.2%
1 month
13.57%
1 year
118.9%
YTD
41.67%
QTD
13.09%

Financial performance

How have Altimmune's revenue and profit performed over time
Revenue
$6.81M
Gross profit
$6.81M
Operating income
-$62.35M
Net income
-$60.02M
Gross margin
100%
Net margin
-881.4%
Altimmune's net income has shrunk by 169% YoY and by 22% QoQ
Altimmune's operating income has plunged by 136% YoY and by 14% from the previous quarter
The net margin has dropped by 100% year-on-year and by 47% since the previous quarter
The operating margin has dropped by 75% year-on-year and by 37% since the previous quarter

Growth

What is Altimmune's growth rate over time

Valuation

What is Altimmune stock price valuation
P/E
N/A
P/B
2.41
P/S
91.32
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
68.08
Altimmune's EPS has decreased by 34% YoY and by 6% QoQ
The P/B is 51% higher than the 5-year quarterly average of 1.6 and 21% higher than the last 4 quarters average of 2.0
The equity has increased by 9% since the previous quarter
ALT's P/S is 59% above its last 4 quarters average of 57.5
ALT's revenue is up by 35% year-on-year but it is down by 17% since the previous quarter

Efficiency

How efficient is Altimmune business performance
Altimmune's return on sales has shrunk by 80% YoY and by 37% QoQ
The return on equity rose by 31% year-on-year and by 11% since the previous quarter
ALT's ROA is up by 28% YoY and by 8% QoQ
The company's return on invested capital rose by 27% YoY and by 13% QoQ

Dividends

What is ALT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALT.

Financial health

How did Altimmune financials performed over time
The total liabilities is up by 44% year-on-year but it has declined by 7% since the previous quarter
Altimmune's current ratio has increased by 30% from the previous quarter
The debt is 100% smaller than the equity
The equity has increased by 9% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.